Wells Fargo Maintains ResMed at Equal-Weight, Raises Target to $250
Wells Fargo maintained its Equal-Weight rating and raised its ResMed price target to $250 from $215.
Wells Fargo maintained its Equal-Weight rating and raised its ResMed price target to $250 from $215.